Deep resequencing of serial sputum isolates of Mycobacterium tuberculosis during therapeutic failure due to poor compliance reveals stepwise mutation of key resistance genes on an otherwise stable genetic background

Journal of Infection

Volumn 62, Issue 3, 2011, Pages 212-217

  Saunders, Nigel J ^a   Trivedi, Urmi H ^b   Thomson, Marian L ^b   Doig, Christine ^c   Laurenson, Ian F ^c   Blaxter, Mark L ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

Drug resistance; Genome sequencing; Isoniazid; Mutation; Rifampicin; Tuberculosis

Indexed keywords

ISONIAZID; KATG PROTEIN; RIFAMPICIN; RNA POLYMERASE BETA SUBUNIT;

ADULT; AMINO ACID SUBSTITUTION; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL GENOME; BACTERIAL STRAIN; BACTERIUM ISOLATE; CASE REPORT; CONTROLLED STUDY; DRUG ACTIVITY; DRUG TREATMENT FAILURE; GENE DELETION; GENE INSERTION; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; MALE; MYCOBACTERIUM TUBERCULOSIS; PATIENT ATTITUDE; PATIENT COMPLIANCE; POINT MUTATION; SPUTUM ANALYSIS; TUBERCULOSIS; VARIABLE NUMBER OF TANDEM REPEAT;

ANTITUBERCULAR AGENTS; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; EVOLUTION, MOLECULAR; GENOMIC INSTABILITY; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MUTATION, MISSENSE; MYCOBACTERIUM TUBERCULOSIS; SPUTUM; TREATMENT FAILURE; TUBERCULOSIS, PULMONARY;

EID: 79952188717     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2011.01.003     Document Type: Article

References (30)

1. Musser J.M. Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clin Microbiol Rev 1995, 8:496-514.
2. Ramaswamy S., Musser J.M. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis 1998, 79:3-29.
3. Gagneux S., Long C.D., Small P.M., Van T., Schoolnik G.K., Bohannan B.J. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 2006, 312:1944-1946.
4. Mitchison D.A. Problems of drug resistance. Br Med Bull 1954, 10:115-124.
5. Mizrahi V., Anderson S.J. DNA repair in Mycobacterium tuberculosis. What have we learnt from the genome sequence?. Mol Microbiol 1998, 29:1331-1339.
6. Mena A., Smith E.E., Burns J.L., Speert D.P., Moskowitz S.M., Perez J.L., et al. Genetic adaptation of Pseudomonas aeruginosa to the airways of cystic fibrosis patients is catalyzed by hypermutation. J Bacteriol 2008, 190:7910-7917.
7. Dos Vultos T., Mestre O., Rauzier J., Golec M., Rastogi N., Tonjum T., et al. Evolution and diversity of clonal bacteria: the paradigm of Mycobacterium tuberculosis. PLoS One 2008, 3:e1538.
8. Dos Vultos T., Mestre O., Tonjum T., Gicquel B. DNA repair in Mycobacterium tuberculosis revisited. FEMS Microbiol Rev 2009, 33:471-487.
9. Springer B., Sander P., Sedlacek L., Hardt W.D., Mizrahi V., P.Schär, et al. Lack of mismatch correction facilitates genome evolution in mycobacteria. Mol Microbiol 2004, 53:1601-1609.
10. Bergval I.L., Klatser P.R., Schuitema A.R.J., Oskam L., Anthony R.M. Specific mutations in the Mycobacterium tuberculosis rpoB gene are associated with increased dnaE2 expression. FEMS Microbiol Lett 2007, 275:338-343.
11. Boshoff H.I.M., Reed M.B., Barry C.E., Mizrahi V. DnaE2 polymerase contributes to in vivo survival and the emergence of drug resistance in Mycobacterium tuberculosis. Cell 2003, 113:183-193.
12. Chan J., Xing Y., Magliozzo R.S., Bloom B.R. Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages. J Exp Med 1992, 175:1111-1122.
13. Cooper A.M., Segal B.H., Frank A.A., Holland S.M., Orme I.M. Transient loss of resistance to pulmonary tuberculosis in p47(phox-/-) mice. Infect Immun 2000, 68:1231-1234.
14. Piddington D.L., Fang F.C., Laessig T., Cooper A.M., Orme I.M., Buchmeier N.A. Cu, Zn superoxide dismutase of Mycobacterium tuberculosis contributes to survival in activated macrophages that are generating an oxidative burst. Infect Immun 2001, 69:4980-4987.
15. Zheng H., Lu L., Wang B., Pu S., Zhang X., Zhe G., et al. Genetic basis of virulence attenuation revealed by comparative genomic analysis of Mycobacterium tuberculosis strain H37Ra versus H37Rv. PLoS One 2008, 3:e2375.
16. Ioerger T.R., Feng Y., Ganesula K., Chen X., Dobos K.M., Fortune S., et al. Variation among genome sequences of H37Rv strains of M. tuberculosis from multiple laboratories. J Bacteriol 2010, 192:3645-3653.
17. Schürch A.C., Kremer K., Kiers A., Daviena O., Boeree M.J., Siezen R.J., et al. The tempo and mode of molecular evolution of Mycobacterium tuberculosis at patient-to-patient scale. Infect Genet Evol 2010, 10:108-114.
18. Broad Institute TB web site: http://www.broad.mit.edu/annotation/genome/mycobacterium_tuberculosis_spp/ToolsIndex.html.
19. Zerbino R., Birney E. Velvet: algorithms for de novo short read assembly using Bruijn graphs. Genome Res 2008, 18:821-829.
20. Li H., Ruan J., Durbin R. Mapping short DNA sequencing reads and calling variants using mapping quality scores. Genome Res 2008, 18:1851-1858.
21. Zhao X., Yu H., Yu S., Wang F., Sacchettini J.C., Magliozzo R.S. Hydrogen peroxide-mediated isoniazid activation catalyzed by Mycobaterium tuberculosis catalase-peroxidase (KatG) and its S315T mutant. Biochemistry 2006, 45:4131-4140.
22. Telenti A., Imboden P., Marchesi F., Lowrie D., Cole S., Colston M.J., et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993, 341:647-650.
23. Billington O.J., McHugh T.D., Gillespie S.H. Physiological cost of rifampin resistance induced in vitro in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1999, 43:1866-1869.
24. Morlock G.P., Plikaytis B.B., Crawford J.T. Characterization of spontaneous, in vitro-selected, rifampicin-resistant mutants of Mycobacterium tuberculosis Strain H37Rv. Antimicrob Agents Chemother 2000, 44:3298-3301.
25. Zaczek A., Brzostek A., Augustynowicz-Kopec E., Zwolska Z., Dziadek J. Genetic evaluation of relationship between mutations in rpoB and resistance of Mycobacterium tuberculosis to rifampin. BMC Microbiol 2009, 9:10.
26. Miotto P., Saleri N., Dembelé M., Ouedraogo M., Badoum G., Pinsi G., et al. Molecular detection of rifampicin and isoniazid resistance to guide chronic TB patient management in Burkino Faso. BMC Infect Dis 2009, 9:142.
27. Gill W.P., Harik N.S., Whiddon M.R., Liao R.P., Mittler J.E., Sherman D.R. A replication clock for Mycobacterium tuberculosis. Nat Med 2009, 15:211-214.
28. Drake J.W. A constant rate of spontaneous mutation in DNA-based microbes. Proc Natl Acad Sci U S A 1991, 88:7160-7164.
29. Bergval I.L., Schuitema A.R.J., Klatser P.R., Anthony R.M. Resistant mutants of Mycobacterium tuberculosis selected in vitro do not reflect the in vivo mechanism of isoniazid resistance. J Antimicrob Chemother 2009, 64:515-523.
30. Weiner M., Burman W., Vernon A., Benator D., Peoloquin C.A., et al. Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am J Respir Crit Care Med 2003, 167:1341-1347.